WCLC 2024
WCLC 2024
Advertisement
Yixian Chen, PhDWCLC 2024 | November 5, 2024
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
View More
Arthi Sridhar, MDWCLC 2024 | October 30, 2024
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Matthew Smeltzer, PhDWCLC 2024 | October 29, 2024
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MDWCLC 2024 | October 28, 2024
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
Didier Debieuvre, MDWCLC 2024 | October 25, 2024
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
Cecilia BrownWCLC 2024 | October 22, 2024
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Roselle De Guzman, MDWCLC 2024 | October 21, 2024
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
Sun ChoiWCLC 2024 | October 18, 2024
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Shirish M. Gadgeel, MDWCLC 2024 | October 15, 2024
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Michael R. Gieske, MDWCLC 2024 | October 11, 2024
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPHWCLC 2024 | October 10, 2024
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Jamie L. Studts, PhDWCLC 2024 | October 8, 2024
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Cecilia BrownWCLC 2024 | October 7, 2024
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Robert E. Merritt, MD, MBA, FACSNon-Small Cell Lung Cancer | October 2, 2024
Robert E. Merritt, MD, MBA, FACS, discusses the analysis he presented at the IASLC 2024 World Conference on Lung Cancer.
Jorge Nieva, MDWCLC 2024 | September 27, 2024
The real-world study was presented at the IASLC 2024 World Conference on Lung Cancer.
Christian Rolfo, MD, PhDWCLC 2024 | September 26, 2024
Dr. Rolfo discusses results of an analysis that evaluated the impact of BMI on TTFields therapy.
Natasha Leighl, BSc, MMSc, MDWCLC 2024 | September 24, 2024
Dr. Leighl explains PALOMA-3 data presented at the IASLC 2024 World Conference on Lung Cancer.
John Wrangle, MD, MPHWCLC 2024 | September 23, 2024
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
Cecilia BrownNon-Small Cell Lung Cancer | September 18, 2024
Researchers shared an updated safety analysis from the trial at the IASLC 2024 World Conference on Lung Cancer.
Ken Culver, MDWCLC 2024 | September 17, 2024
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Advertisement
Advertisement
Advertisement
Latest News

December 9, 2024